On Aug. 31, Eli Lilly & Co. (NYSE: LLY) announced its intention to acquire Merida Biosciences for $2.875 billion. The acquisition will expand Lilly's portfolio for serious autoimmune and allergic diseases.
Merida's lead drug candidate, MER511, is in Phase 1 development for the treatment of Graves' disease and thyroid eye disease (TED). Graves' disease affects approximately three million people in the United States. Roughly 25% to 40% of patients with Graves' disease go on to develop TED.
If approved, MER511 will be the first approved treatment for both conditions that directly target the autoantibodies that cause them. This acquisition fits with Lilly's strategy of building its pipeline "around therapies that meaningfully change the course of disease, not just its downstream effects."
The deal is also one of the first examples of how Lilly is using the financial strength being created by its GLP-1 franchise to diversify its pipeline, particularly in immunology.
The Merida Deal Shows How Lilly Is Thinking Beyond GLP-1
On its own, $2.875 billion is a rounding error for a company with Lilly's market cap. But the Merida deal is about what it signals rather than what it costs. In Lilly's case, it's a tell about how management is thinking about the next phase of the GLP-1 story.
Every mega-cap drugmaker eventually faces the same question after a period of explosive, single-franchise growth: Is this durable, or is it a supercycle that fades once patent cliffs, competition, or payer pushback catch up?
Lilly's answer, at least so far, is to plow GLP-1 cash flow into adjacent, higher-conviction disease areas rather than simply defending its current lead. That's a different posture than a company milking a hit product — and it's the detail investors should weigh before turning to the obesity and diabetes headlines below.
Lilly Is Using GLP-1 Strength to Build Beyond Obesity
Eli Lilly is one of the most well-known and well-respected names in the biotechnology sector. Quarter after quarter, and now year over year, Lilly is showing why it's the king of the growing GLP-1 sector.
Recent clinical trial results show it has no intention of giving up that crown anytime soon. Those trials center on expanding the label for
Regarding its obesity drug, Zepbound, Lilly recently released one-year Phase 3b results that show a combination of Zepbound with Taltz produced durable improvements in psoriasis and psoriatic arthritis, in addition to improving or sustaining weight and metabolic outcomes.
Plus, Mounjaro, its type 2 diabetes drug, has received an FDA expansion that approves the drug to reduce cardiovascular risk. This expands the drug's addressable market and may help offset concerns that employers and payers will reduce coverage of GLP-1 medicines heading into 2027.
LLY Stock Is Still Trailing Healthcare Despite Strong Results
But it might surprise some investors to know that an investment in LLY would be underperforming the Health Care Select SPDR Fund (NYSEARCA: XLV), one of the leading exchange-traded funds in the sector.
To be fair, it's close. LLY has increased by nearly 8%, and XLV has risen about 10% so far this year. Also muddying the waters is the fact that LLY is the XLV's largest holding by weight at just over 15%.
Lilly’s Pipeline Gives the Stock More Than a GLP-1 Story
This is the broader issue for investors to consider. LLY has been on a strong five-year run that has pushed the stock price up approximately 350%. Investors who have reinvested the company's dividend, which currently yields about 0.60%, have received a total return of over 370% in that same period.
The company's Q2 2026 earnings report showed an almost 48% year-over-year (YOY) gain on the top line and a 32% YOY increase in adjusted earnings per share (EPS). Furthermore, Lilly raised its full-year guidance for the top and bottom lines.
Those results speak to the company's leadership in GLP-1. But even before the Meridan acquisition, Lilly had one of the deepest pipelines in the industry, which includes Cardiometabolic Health, Immunology, Neuroscience, and Oncology. Over 40 of the drugs in the company's pipeline are in Phase 3 trials. That gives investors a line of sight to future revenue and earnings growth.
Valuation Is the Real Test for LLY Stock Now
Surprisingly, even at around 38x earnings, LLY isn't overvalued by its historical standards. That said, as of early September, the stock is within about 11% of its consensus price target of $1,292.18. Several analysts have raised their price targets since the company's last earnings report, which suggests the Street still sees room to run. But a stock trading close to consensus, after a nearly 350% five-year gain, is also one with less room for error.
To be fair, Lilly has earned its "GLP-1 king" reputation on results, not hype. The company's pipeline was already deep, and the Merida deal shows a company thinking several moves ahead.
Nevertheless, Lilly is now in a period where that growth may be getting priced in. LLY's underperformance relative to XLV year-to-date is a reminder that even best-in-class execution doesn't guarantee outperformance when expectations have run ahead.
GLP-1 Coverage Risks Could Challenge Lilly in 2027
Another thing for investors to consider is the 2027 payer-coverage overhang on GLP-1 pricing. That makes the setup not "buy the king unconditionally" so much as "the king's crown is real, but the price of admission has gotten steeper along with it."
Investors comfortable paying up for quality and duration have a reasonable case. Those looking for a margin of safety may want to wait for a pullback, a trial disappointment, or a guidance reset to create one.